Australia markets closed

Zealand Pharma A/S (ZEAL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
20.00-0.71 (-3.43%)
At close: 01:48PM EST
Full screen
Trade prices are not sourced from all markets
Previous close20.71
Open20.00
Bid19.64 x 1100
Ask20.41 x 900
Day's range19.40 - 20.00
52-week range19.33 - 38.21
Volume9,898
Avg. volume5,691
Market cap864.31M
Beta (5Y monthly)1.08
PE ratio (TTM)N/A
EPS (TTM)-4.03
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.52
  • Zacks

    Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study

    Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

  • GlobeNewswire

    Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

    Company announcement – No. 3 / 2022 Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Full trial results of EASE-SBS 1 expected in the third quarter of 2022Pending positive pivotal data, Zealand intends to file for marketing approval with the U.S. Food and Drug Administration Copenhagen, DK and Boston, MA, U.S. January 20, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the

  • GlobeNewswire

    Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022

    Company announcement – No. 2 / 2021 Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022 Copenhagen, DK and Boston, MA, January 19, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareho